
October 30, 2024
US-focused Hydration solutions company, The Hydration Pharmaceuticals Company Limited (ASX: HPC) (“Hydralyte USA” or “the Company”) is pleased to provide the following update on its operational and financial performance for the three-month period ended 30 September 2024 (the “quarter”).
KEY HIGHLIGHTS
- Positive net operating cash flows of US$0.6m – marks maiden positive operating cashflow quarter and validation of Company’s push to profitability
- Revenue for the period of US$2.4m – underpinned by US$1.21m in ecommerce sales, aligned with the Company’s revised strategy of driving online sales
- 54% reduction in adjusted EBITDA loss on PCP to -$0.6m (Q3 FY23: -$1.3m) – second consecutive record low since IPO
- Gross margin up 7% on last quarter to 61% and +3% on PCP
- Marketing costs as a percentage of net revenue were 24%, down 30% in the PCP
- Divesture of non-US assets to Prestige Consumer Healthcare Inc and associated subsidiaries completed post quarter end
- Total proceeds of ~US$9.5m (A$13.7m) included US$8.3m for all non-US territories plus US$1.2m for stock and inventory (subject to final adjustments).
- Company retains full ownership of US-based operations, which are achieving annualised revenue of US$3.5m (unaudited, based on Q3 FY24 annualised)
- US assets have considerable scope to grow with recently introduced cost efficiencies – Ongoing focus on achieving cashflow breakeven
- Divesture allows for repayment of debt with objective to fund the Company on a reduced size and expense base for a minimum of twelve months
- Near-term growth strategy will focus on scaling ecommerce channels and products - follows recent momentum on Amazon USA, which has generated five consecutive months of positive net contribution margin
Financial overview:
During the quarter, the Company continued to deliver on its stated strategy of maintaining sales, while delivering a material reduction in operating expenses.
The focus on profitability and cash preservation resulted in HPC’s maiden quarter of positive net cash from operating activities of $0.6m, compared to a loss of US$0.8m in the previous quarter, and a loss of US$1.5m in Q3 FY23. The significant improvement was a result of the continued reduction in expenses, as well as more favourable payment terms negotiated with suppliers.
Revenue for the quarter remained relatively consistent at US$2.4m underpinned by sales across North America and a reduction in marketing and advertising expenses and unprofitable SKUs in order to prioritise cash preservation and profitability. This led to improvements to net margin, cash flow, and EBITDA.
EBITDA loss decreased 54% on PCP (Q3 FY23: US$1.3m) to a record low of US$0.6m. A result of the continued strong gross profit combined with reduced expenses.
Click here for the full ASX Release
This article includes content from The Hydration Pharmaceuticals Company Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.
HPC:AU
The Conversation (0)
30 May 2024
Hydralyte International
Overview
Hydralyte International (ASX:HPC) is an ASX-listed rapid hydration solutions business focused on the lucrative North American market. With an established supply chain in Canada and the United States, the company consolidated its market position in FY23 with a 10 percent increase in net sales to $10 million. The impressive increase in group sales was achieved with a disciplined cost focus which flowed through to a significant US$5.7 million in cash savings. And there was ongoing momentum in the first quarter of FY24, with consistent growth in net sales to US$2.17 million on strong gross margins of 56 percent.
Hydralyte’s multi-channel distribution strategy includes a targeted growth through ecommerce. Its rapid rehydration product has been the number one SKU in the hydration category on Amazon Prime Day in Canada, where it's the number two hydration brand overall with a 21 percent market share. Starting on Prime Day, Hydralyte delivered ~US$140,000 in gross sales over 48 hours.
It's also worth noting that all this revenue growth – alongside a partnership with Shay Mitchell – occurred with an ongoing reduction in marketing expenditure. In 2024, marketing costs as a percentage of net revenue decreased to 37 percent from 48 percent in Q1 2023. This is due in part to the company's solid leadership team, featuring professionals with decades of expertise in health and wellness, as well as heavy brand investments which have been made throughout 2022.
In Australia, New Zealand and parts of Southeast Asia, Prestige Consumer Healthcare (NYSE:PBH) holds the exclusive sales and distribution rights to Hydralyte products. PBH is an American over-the-counter healthcare marketing and distribution company, dating back more than 100 years.
Hydralyte International's robust supply chain, sales trajectory, manufacturing approach and product strategy are far from the only reasons it shows such promise as an investment. Current market trends also significantly favor the company's core value proposition. Valued at US$1.68 billion in 2023, the global electrolyte hydration drinks market is expected to reach US$2.78 billion by 2033 as consumers turn away from high-sugar, low-electrolyte drinks and towards more clinical hydration products.
Roughly 75 percent of Americans are dehydrated at any given time. The reasons are many and varied, ranging from travel and exercise to alcohol and illness. Its symptoms are something many of us have simply learned to live with – irritability, brain fog, dizziness, increased thirst, dry mouth and fatigue, to name just a few.
Hydralyte fits the bill perfectly for these consumers. Founded with the goal of making a difference through better hydration, Hydralyte is able to treat dehydration more effectively than the majority of sports drinks on the market. Thanks to its proprietary formula – which uses a precise ratio of water, electrolytes and glucose based on the World Health Organization's recommended formula for rapid rehydration.
Hydralyte is available in three forms: ready-to-drink, tablet and dissolvable powder stick. All three are widely accepted in the medical community. Hydralyte is also frequently used by professional athletes as an alternative to sports drinks.
In short, thanks to its market position, strong leadership and science-based formula, Hydralyte represents the perfect opportunity for investors to enter the lifestyle sports market.
Get access to more exclusive Biotech Investing Stock profiles here
Keep reading...Show less
Leveraging a Rapidly Expanding Hydration Market in North America
31 January
Q4 FY24 Quarterly Activities Report (App 4C)
Latest News
Latest Press Releases
Admission to Trading on the OTCQB Market
12 September
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00